• We acquired Pharma Waldhof, a distributor of biopharmaceuticals, from Roche. The acquisition, which was immediately accretive to Aceto's earnings, enabled us to enter the biopharmaceuticals market. Our biopharmaceutical business is included within our Health Sciences segment. Additionally, we are engaged in development activities to enter the emerging generic biopharmaceuticals segment.
  
  
• In line with our plan to expand our Agrochemicals segment, we formed a joint venture with Nufarm Limited to capitalize on the imminent shift in the agrochemical supply channels. The joint venture acquired the EPA labels for the herbicide Butoxone(R) and began marketing the product, which has contributed to the strong performance of our Agrochemicals segment.
  
  
• We opened an office in Poland through which we are working with pharmaceutical manufacturers in the ten countries that recently joined the EU, supplying them with EU-approved active pharmaceutical ingredients (APIs). We have begun to generate sales through this initiative.

• We are moving forward with the market development of products for the emerging generic biopharmaceutical industry. In this regard, we expect to generate initial commercial sales in the next 18 months based on certain regulatory pathways already in place.
  
  
• Another area of potential growth for Aceto is organic color pigments, one of the fastest growing segments of the chemical industry due to the increasing use of color in newspapers and magazines. We have been conducting market development in this area for over a year, and have begun to record commercial sales.
  
  
• Additionally, the Company has developed a patent-pending product that abates odors emitted from landfills, which is an important environmental, health and safety issue. Initial feedback from the market has been very positive, and one major landfill operator plans to commence a full-scale test shortly."

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on current expectations, estimates and projections made by management. The Company intends for the forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," or variations of such words are intended to identify such forward-looking statements. The forward looking statements contained in this press release include, but are not limited to, developing products for the generic biopharmaceuticals segment, expectation of sales in the next 18 months in the generic biopharmaceuticals segment, the development and testing of a landfill odor product, and the earnings guidance for the Company's first quarter of fiscal 2005. All forward-looking statements in this press release are made as of the date hereof, and the Company assumes no obligation to update these forward-looking statements whether as a result of new information, future events or otherwise, other than as required by law. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. These uncertainties include, but are not limited to, the mix of products sold and the profit margins thereon, order cancellation or a reduction in orders from customers, competitive product offerings and pricing actions, the availability and pricing of key raw materials, dependence on key members of management, risk of entering into new European markets, continued successful integration of acquisitions, economic and political conditions in the United States and abroad, as well as other risks detailed in the Company's SEC reports, including the Company's Form 10-K and other filings. Copies of these filings are available at www.sec.gov.